The Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and European Group for Blood and Marrow Transplantation (EBMT), known as JACIE, is a nonprofit body established for the purposes of assessment and accreditation in the field of haemopoietic SCT (HSCT). The committee was established in 1999 with the aim of creating a standardized system of accreditation officially recognized across Europe and based on the accreditation standards established by the US-based Foundation for the Accreditation of Cellular Therapy (FACT). The major objectives of JACIE are to improve the quality of HSCT in Europe by providing a means whereby transplant centres, cell collection facilities and processing facilities can demonstrate high-quality practice. JACIE launched its official inspection programme in January 2004, and since then more than 35 centres in Europe have been inspected. The history of paediatric-specific accreditation guidelines has lagged behind the overall development but is now incorporated within the standards. There is now acknowledgement that a paediatric transplant team will be headed by a paediatric programme director, that an independent paediatric unit will perform no less than 10 allogeneic transplants in children under the age of 18 per year, be looked after by nurses and junior doctors specifically trained in paediatric practice and have access to paediatric subspecialties with an intensive care unit on site. Paediatric units will be examined by a paediatric-trained inspector. Remaining issues of difference with the guidelines relate to the numbers required for accreditation in combined units. Overall, the paediatric community in Europe has embraced the JACIE guidelines. JACIE is working more closely with other international organizations in cellular therapy to develop international standards for all aspects of SCT. The recent implementation of Directive 2004/23/EC has provided an impetus for the implementation of JACIE in European Union (EU) member states, and in particular the requirements for safety of imported tissues and cells have emphasized the need for global harmonization. 
The JACIE process
The requirement to demonstrate the quality of practice has rightly become one of the chief priorities for health care professionals. There is heightened concern for the welfare of patients, increased pressure from funding bodies to demonstrate value for money and now raised fears of negligence and litigation. Governments and insurance companies are demanding that practitioners demonstrate that their activity and practices are in accordance with minimum standards of care. Accreditation is the means by which a centre can demonstrate that it is performing to a required level of practice in accordance with agreed standards of excellence. It allows a centre to certify that it operates an effective quality management system (QMS). A QMS is a mechanism to ensure that procedures are being carried out in line with agreed standards and full participation by all members of staff. In a SCT programme, this assumes that the clinical collection and laboratory units are all working together to achieve excellent communication, effective common working practices and increased guarantees for patient safety. A QMS is a means of rapidly identifying errors or accidents and resolving them so that the possibility of repetition is minimized. It assists in training and clearly identifies the roles and responsibilities of all staff. Once the required level of quality has been achieved, the remaining challenge is to maintain this standard of practice. With a working QMS in place and adequate resources, the fundamental elements necessary to sustain the programme are continued staff commitment, vigilance and regular scrutiny and an update of operational protocols.
The European Union (EU) Directive 2004/23/EC 1 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells entered into force in all EU member states on 7 April 2006, and member states had to implement the directive through national legislation until April. Many countries have looked at the implications of the directive and are consulting with healthcare experts and advising on measures to fulfil the requirements. However, the potential costs and complications of setting up an accreditation system are becoming apparent. The Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and European Group for Blood and Marrow Transplantation (EBMT) known as JACIE, offers a cost-effective solution on a Europe-wide basis, contributing harmonization of systems and practice, and is now rapidly becoming the universally accepted standard for quality medical and laboratory practice in haemopoietic (HSCT) in Europe. It is firmly supported in Austria, the United Kingdom, Spain, Germany, France, Belgium, Switzerland, The Netherlands, Italy and some of the Nordic countries and has started its expansion among the new member states of the EU.
JACIE offers a set of established and globally recognized standards that more than satisfies the requirements of the EU directive. JACIE can support health authorities with an already existing structure consisting of a central secretariat, a board, which since the early 1990s has had a paediatric representative from the EBMT Paediatric Disease Working Party as one of its members, and a network of qualified and trained inspectors with invaluable experience in the area of accreditation. In turn, health authorities can assist by recognizing JACIE's contribution to improving standards of clinical practice.
JACIE is a nonprofit body whose committee was founded in 1998 by the EBMT and the ISCT, the two leading scientific organizations involved with HSCT in Europe. 2 JACIE modelled itself on the US-based Foundation for the Accreditation of Cellular Therapy (FACT) established in 1996 by the ISCT and the American Society for Blood and Marrow Transplantation (ASBMT). JACIE actively collaborates with FACT in establishing standards for the provision of quality medical and laboratory practice. JACIE conducts inspections, accredits programmes and encourages health institutions and facilities performing HSCT to meet these standards voluntarily to demonstrate their high levels of quality of care.
The primary aim of JACIE is to improve the quality of HSCT in Europe by providing a means whereby transplant centres, cell collection facilities and processing facilities can demonstrate high-quality practice. This is supported by coordinating training courses in quality management for applicant centres and courses for inspectors. An additional and wider aim is to ensure harmonization between JACIE standards and other national/international standards including the EU Tissues and Cells Directive (Directive 2004/23/ EC) and the related implementing directives. The increasing use of unrelated donor cells for transplants highlights the need for much more work in this area.
Accreditation of HSCT facilities is through online submission of documentation and an onsite visit by a team of trained inspectors. Centres may apply for accreditation as complete programmes comprising a clinical programme, a collection facility and a processing laboratory or for example, as a single collection or processing facility serving a number of clinical programmes. JACIE accreditation is voluntary, but provides a means whereby transplant facilities can demonstrate that they are working with a quality system covering all aspects of the transplantation process. They can thus show compliance with the requirements of insurance companies or national and/or international regulatory authorities.
The JACIE standards
The JACIE standards 3 cover all aspects of clinical transplant programmes, collection facilities (BM collection and peripheral blood progenitor cell collection) and processing. The Standards also apply to the use of therapeutic cells derived from blood or marrow including donor lymphocytes and mesenchymal stem cells.
Within each subsection are detailed lists of specific standards. For example, under clinical programme, the broad headings include size and organisation, facilities, staffing, quality management programme, policies and procedures, donor evaluation and selection, administration of high-dose therapy, clinical research, data management and records. The complete standards and the accompanying guidance manual are available on the JACIE website.
JACIE standards conform to the tissues and cells directive not only as regards donation, procurement and processing of stem cells but also cover clinical transplant programmes. Accreditation of clinical programmes includes the clinical use of cord blood stem cells, but the JACIE programme does not accredit to cord blood collection and banking facilities as this process is currently being carried out by Netcord FACT. 4 The third addition of the standards was released in February 2007 and entered into use on 19 August 2007.
The JACIE manual and inspection checklist contains the standards together with detailed guidance on the interpretation and measures required to demonstrate compliance. Each standard is followed by specific questions relating to that standard and these questions form the basis of the inspection checklist. These must be completed before inspection by the applicant centre and verified by the inspector during the inspection.
The accreditation process
The centre, by way of preparation, implements measures as described in the JACIE accreditation manual and then applies for inspection by submitting basic information about the programme/facility and a number of supporting documents, including a self-assessment checklist. The application information and checklist must be submitted in English, but all other documentation, including Standard Operating Procedures (SOPs) is accepted in the language of the centre.
An onsite visit is carried out by a team of trained inspectors, usually one per facility, and these inspectors are medical, scientific or other professional people working in HSCT with specific qualification and experience for inspecting clinical collection and/or processing facilities. 5 Inspectors must have attended a JACIE-sponsored training course and have passed an examination. An inspection visit will usually last 1-2 days and involves discussion with staff during their work, review of documents and records and completion of a detailed checklist relating to the standards. The inspectors write a report in English noting any areas of noncompliance with the standards, and this is then reviewed by the JACIE office. On the basis of the inspector's findings, a supplementary report from the JACIE medical director is prepared indicating the current level of compliance and making specific recommendations for corrections and improvements.
Between 3 and 12 months is allowed for the centre to correct deficiencies depending on the amount of work required. The inspection report and medical director's report are approved by the JACIE Executive Committee and then issued to the applicant centre. The JACIE Accreditation Committee has been established and takes over this role currently.
The centre must indicate acceptance of the findings and then in due course submit documentary evidence to confirm the corrections or amendments. The medical director then reviews all the reports and relevant documentation and, if satisfied that all previous deficiencies have been corrected, the JACIE Accreditation Committee makes a recommendation to the JACIE Board that the centre be awarded accreditation. If approved, accreditation is awarded and this is now valid for 4 years subject to an annual report from the centre noting any significant changes in personnel or procedures and including annual activity figures.
In terms of the common difficulties encountered, it is observed that it takes at least 18 months for preparation towards JACIE accreditation, and staff other than the programme director normally have to manage the project implementation. Most frequently, extra resources are required, including a quality manager and data manager, which usually necessitates some additional financial support. The greatest difficulty is generally found in implementing the QMS, which arises from a lack of trained staff and absence of a quality management culture particularly in the clinical setting. This illustrates that there is clearly an important need for training of clinical staff, such as doctors and nurses and quality management, and it is also important for centres to have a designated quality manager who has appropriate experience in QMS. An excellent Quality Management Guide has just been published in 2008 with European authors contributing to this first edition of the Quality Management Guide. The objective is to offer a clear practical and simple approach to the challenges faced when setting up and maintaining a quality management programme and the hope is that it will become an indispensable tool for both professional quality managers and novices to the area. Everyone who has been involved in this educational project is convinced that sharing knowledge and experience is an essential part of making quality management relevant and effective in the work place and ultimately helping to provide the best possible care to patients and donors. This guide is available from the JACIE office.
JACIE in paediatrics
The history of paediatrics within the JACIE process has been a long and difficult one. Once it was realized, however, that there was a need to acknowledge that the specific needs of paediatric practice with a concept of raising the standards for children rather than diluting the guidelines, there was a cautious acceptance from the JACIE Board. It was acknowledged at the EBMT meeting in Barcelona in March 2001 that appropriate and specific standards for paediatric transplantation should be incorporated into the JACIE manual, and there was a proposal that these standards would be discussed within the JACIE and FACT Boards to potentially include in the next version of the standards. In fact, any reference to paediatrics did not occur until beyond 2004 when parallel standards for paediatrics was accepted but easy dialogue was impeded by a rather entrenched stance, which was defined by political expediency and physician preference rather than what the Paediatric Diseases Working Party of the EBMT would describe as best care of the child. Nonetheless, there are now paediatric guidelines side by side with the standard recommendations in the third edition of the standards such that it is acknowledged that HSCT in children and adolescence up to the age of 18 years must be performed by a designated paediatric transplant team and should be treated in a paediatric programme headed by a paediatric programme director. There is still an issue with the EBMT regarding age as the adult working parties continue to collect data on adolescents from 16 years and above, whereas paediatricians incorporate 18-year-olds into their data collection. A paediatric programme may operate either within a larger transplant unit side by side with an adult programme, or more commonly, operate as an independent unit.
Centres performing paediatric BM harvests should have appropriate operating theatres and specialist paediatric anaesthetists, whereas centres performing leukophoresis for PBSC or leukocyte donation should have appropriate equipment for small children and staff trained in paediatric resuscitation.
A minimum of 10 allogeneic paediatric (o18 years of age) transplants should have been performed during the year before the application for programme accreditation (in certain agreed countries, this may be an average of 10 per year). This minimum of 10 allogeneic transplants in paediatric patients should also be required in combined programmes where both children by a paediatric team and adults are transplanted. 6 FACT JACIE does not, at this moment, acknowledge this to be the case and takes a total of 10 transplants which may be either five paediatric or five adult or any combination, to be the accreditation figure.
This latter point is highly controversial. There is ample published evidence that there is a centre effect associated with survival irrespective of which type of transplant is performed, and although JACIE does not look at the outcome; nonetheless, all members of the Paediatric Diseases Working Party within the EBMT are unanimous in recognizing that in assessing the quality of environment even if not outcome, child appropriate facilities and multidisciplinary staff have to be available for the best care of the child.
Another conflicting point is that centres that perform only autologous transplants in children are generally subject to an accreditation procedure for specialist paediatric oncology units, these autograft procedures usually only take place within specialist units and these children are usually entered on nationally directed and accredited protocols. This differs from adult practice.
It is a requirement that the paediatric programme director should be licensed to practise paediatrics in Europe and be trained in paediatric haematology, oncology or immunology. The programme director will oversee the standards for the transplant programme according to good clinical practice and be responsible for clinical governance. The transplant team should include, besides the programme director, at least one other paediatrician trained and experienced in transplantation of children.
Each paediatric transplant programme should have direct access to paediatric subspecialties, particularly paediatric surgery and anaesthesia, paediatric respiratory medicine, gastroenterology, nephrology, cardiology, infectious disease and psychiatry with paediatric radiation oncologists and, most importantly, paediatric intensive care preferably in the same hospital, that is, onsite.
In a paediatric SCT programme, the nurse director must be trained in paediatric SCT and nursing staff trained in the full range and management of paediatric patients in the transplant unit. There should be appropriate staff to maintain the support services particularly paediatric dieticians, pharmacists, physiotherapists and clinical psychologists, and other members of the multi-disciplinary team to include social workers, teachers and play therapists.
In support of the paediatric programme, the collection facility for both BM harvest and PBSC collection will have staff formally trained and experienced in working with paediatric patients and donors and trained in paediatric resuscitation.
As stated before, accreditation of a paediatric SCT unit will involve a visit by paediatric-trained inspectors.
Hence, there is still a little way to go although much ground has been gained for the care of children, which should never be sublimated to the care of adults. There is within the UK ample literature to support that children in hospital must be cared for in a child-centred environment by staff trained in caring for children and in facilities appropriate to their needs where the care of children is given priority. This philosophy covers standards of safety, competence of health care professionals, standards of care and monitoring, and reports have suggested that specialist services for children should be organized so as to provide the best available staff and facilities, thus providing the best possible opportunity for good outcome.
In response to this documentation, the Department of Health within the United Kingdom has acknowledged that children within our society have not always been given the priority they deserve and that it is committed to changing this to ensure that children, similar to adults, are entitled to high quality safe services designed to meet their particular needs. They state that children should not have to make do with services designed for adults, which are inappropriate for them. With bitter lessons learnt from this experience, it would seem appropriate that the rest of Europe should learn and profit from the mistakes of other countries.
JACIE-the future
The future is positive and the work of JACIE continues. Preparation for the fourth edition of the standards, which will be issued as FACT JACIE standards, has commenced with the final release proposed by the end of 2008. JACIE has a representative as cochair on each of the three subcommittees and the paediatric representative on the JACIE Board has taken part during the earlier months of 2008 and contributed to the clinical subcommittee of the FACT JACIE Standards. The JACIE medical director is cochair of the Standards Steering Committee, which oversees the standards revision process.
As stated earlier, the requirements of the EU Directive 2004/23/EC became law in member states on 7 April 2006. The current JACIE Standards conform to the requirements of the directive as regards donation, procurement and processing of stem cells, although JACIE is more detailed in many areas and JACIE standards also cover clinical transplant programmes. JACIE FACT and the World Marrow Donor Association (WMDA) are working together to promote consistent interpretation of the requirements of the directive by the regulatory authorities in the different member states.
Although support for accreditation among the professional transplant community is high, there are varying levels of engagement with JACIE by the regulatory authorities in different countries. It has proven very difficult to build up a standard picture of official support across the EU owing to significant differences in regulatory structures, varying readiness to implement the directive and political issues. However, it can be said that in a number of countries there has been support from the regulatory authorities, both direct and indirect, for the JACIE accreditation system.
It is acknowledged that it is a fundamental aim of JACIE to ensure that the FACT JACIE standards, as far as possible, are identical to other applicable national and international requirements including those of the EU. This is particularly important to prevent difficulties in importing and exporting tissues across international boundaries, which could occur if there were to be differences in the standards adopted in different countries, and hence the close working together of JACIE and FACT. As stated, this resulted in the release of the third edition of the standards and the fourth will be forthcoming at the end of 2008.
One of the results of this collaborative approach has been the establishment of an alliance for the harmonization of cellular therapy accreditation (AHCTA) whose current membership includes: These organizations together commit themselves to pursue the harmonization of their respective standards with the objective of creating a single set of quality, safety and professional requirements for all aspects of cellular therapy from donation to transplantation.
Conclusion
The JACIE accreditation system is now firmly established in Europe, and the experience of centres that have been inspected are that implementation of the JACIE standards has led to significant improvements in different aspects of their transplant programmes. JACIE has further assisted with a number of training courses for preparing centres for accreditation and has issued a practical guide for quality management. JACIE has developed a close working relationship with other organizations involved in cellular therapy, which forms the basis for a new global approach to harmonization of standards and accreditation systems worldwide. This collaboration represents an innovative and proactive approach in solving the problems of international exchange of tissues and cells, as these relate to the SCT community. The progress for paediatrics has been steady and there is now widespread European recognition for the importance of paediatric standards. The next few years hopefully will bring greater proximity and understanding.
